HomeAI · summaries
Storia in 5 fonti
Tempus AI strikes $1.5B deal for Personalis, betting big on AI-powered cancer detection
Tempus AI acquires Personalis for $1.5 billion to expand cancer MRD testing capabilities, targeting a $20 billion market with AI-driven precision oncology.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Tempus to acquire cancer test maker Personalis for $1.5B
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
- ·
fiercebiotech.com
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. | Tempus is boosting its cancer offerings with a…
